샘플 요청 목록

 카트 문의
시장보고서
상품코드
1765053

세계의 유전자 치료 시장

Gene Therapy
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 411 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

유전자 치료 세계 시장은 2030년까지 60억 달러에 이를 전망

2024년에 17억 달러로 추정되는 유전자 치료 세계 시장은 2024-2030년 CAGR 23.0%로 성장하여 2030년에는 60억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 바이러스 분야는 CAGR 23.3%를 나타내고, 분석 기간 종료까지 55억 달러에 이를 것으로 예측됩니다. 비바이러스성 부문의 성장률은 분석 기간중 CAGR 20.8%로 추정됩니다.

미국 시장은 9억 2,890만 달러로 추정, 중국은 CAGR29.5%를 보일 것으로 예측

미국의 유전자 치료 시장은 2024년에 9억 2,890만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 2억 1,630만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 29.5%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 20.1%와 22.1%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 22.0%를 보일 전망입니다.

세계의 유전자 치료 시장 - 주요 동향과 촉진요인 정리

의료에 혁명을 일으킬 유전자 치료는 어떻게 치료 패러다임을 재정의하고 있을까?

유전자 치료는 사람의 세포 내 유전 물질을 변형시켜 질병을 치료하거나 예방하는 획기적인 의료 접근법입니다. 이 혁신적인 치료법은 질병 발생의 원인이 되는 결함 유전자를 교정함으로써 다양한 질병에 대한 치료법을 제공할 수 있습니다. 유전자 치료에 사용되는 기술에는 질병을 유발하는 돌연변이 유전자를 건강한 사본으로 대체하는 것, 부적절하게 기능하는 돌연변이 유전자를 비활성화하는 것, 질병 치료에 도움이 되는 새로운 유전자나 변형된 유전자를 체내에 도입하는 것 등이 있습니다. 이러한 방법은 주로 인간의 DNA를 운반하도록 유전자 변형된 바이러스인 벡터를 통해 이루어집니다. 유전자 치료의 가능성은 낭포성 섬유증이나 혈우병과 같은 유전성 질환의 치료에서 암, 심장병, HIV/AIDS와 같은 더 복잡한 질병에 이르기까지 다양합니다. 그 개발은 기존 치료법에서 큰 도약을 의미하며, 한 번의 치료 과정으로 장기적 또는 영구적인 치료 효과를 기대할 수 있습니다.

한계에 대한 도전 유전자 치료를 강화하는 차세대 기술

CRISPR-Cas9를 비롯한 유전자 편집 기술의 등장으로 과학자들은 특정 위치에서 DNA를 편집할 수 있는 전례 없는 정밀한 도구를 갖게 되었고, 돌연변이가 발생한 지점에서 돌연변이를 교정할 수 있게 되었습니다. 이러한 발전은 치료의 성공 가능성을 높여줄 뿐만 아니라, 기존 유전자 치료법의 위험성(예: 의도파관 않은 유전체의 다른 부분에 미치는 영향)을 줄여줍니다. 또한, 벡터 기술, 특히 비바이러스성 전달 시스템 개발의 혁신은 안전성과 면역 반응 관리와 관련된 기존 문제를 극복하고 있습니다. 이러한 전달 시스템의 강화는 치료용 유전자가 표적 세포에 보다 효과적으로 도달하여 의도한 대로 기능할 수 있도록 보장합니다.

복잡성 극복: 현대의 과제와 윤리적 딜레마 유전자 치료의 과제

유전자 치료는 유망한 잠재력에도 불구하고 임상 적용에 영향을 미치는 몇 가지 도전과 윤리적 고려사항에 직면해 있습니다. 주요 과제 중 하나는 유전자 편집의 장기적인 영향이 아직 충분히 밝혀지지 않았기 때문에 장기적인 안전성과 유효성을 보장하는 것입니다. 의도파관 않은 부분이 편집되어 예상치 못한 결과를 초래할 수 있는 오프 타겟 효과의 가능성에 대한 의문도 남아있습니다. 또한, 바이러스 벡터에 대한 면역 체계의 반응은 특히 벡터로 사용되는 바이러스에 대한 기존 면역이 있을 수 있는 환자의 경우, 도입과 효과를 복잡하게 만들 수 있습니다. 윤리적 문제도 중요한 역할을 하고 있으며, 특히 생식세포 계통 편집과 관련하여 유전적 변화가 다음 세대로 전달될 수 있는 가능성도 있습니다. 논의의 중심은 인류의 진화를 바꿀 수 있는 유전자 변형의 의미이며, 치료법 개발 및 적용에 있어 엄격한 윤리 기준과 규제 감시의 필요성을 강조하고 있습니다.

의료 혁명의 추진력: 유전자 치료 시장 확대의 주요 동인

유전자 치료제 시장의 성장은 유전자 연구와 생명공학 기술의 눈부신 발전 등 여러 요인에 의해 이루어지고 있습니다. 유전성 질환의 유병률 증가와 종양학, 신경학, 희귀질환에서 새로운 치료법에 대한 미충족 수요가 높은 것도 시장 성장 촉진요인으로 작용하고 있습니다. 최근 몇 가지 유전자 치료제가 상업화에 성공하면서 투자 대비 높은 수익률이 입증되었고, 이 분야의 연구개발에 많은 자금이 몰리고 있습니다. 또한, 희귀질환 치료제 지정 및 조기 승인과 같은 규제 우대조치가 희귀질환 및 중증질환에 대한 유전자치료제 개발을 촉진하고 있습니다. 소비자 행동, 특히 개인 맞춤형 의료와 지속적이고 영구적인 치료법에 대한 수요 증가도 시장을 발전시키고 있습니다. 또한, 생명공학 기업, 제약사, 학술 기관 간의 협력은 혁신을 촉진하고 연구부터 임상으로의 전환을 가속화하고 있습니다. 이러한 요인들은 세계 바이오의약품 생산 능력의 향상과 함께 유전자 치료 솔루션의 지속적인 성장과 확장을 보장하며, 현대 의학에서 가장 역동적이고 혁신적인 분야 중 하나로 자리매김하고 있습니다.

부문

벡터 유형(바이러스성, 비바이러스성);용도(암질환, 희귀질환, 심혈관질환, 신경질환, 감염증, 기타 용도)

조사 대상 기업 예

  • Amgen, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Bionomics Ltd.
  • BioMarin Pharmaceutical, Inc.
  • AnGes, Inc.
  • Amicus Therapeutics, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • bluebird bio, Inc.
  • Advantagene, Inc.
  • Biogen, Inc.
  • Abeona Therapeutics
  • Aptah
  • Avrobio
  • Arbor Biotechnologies, Inc.
  • Biocardia, Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 바이러스 벡터가 시장 대부분을 차지한다
  • 비바이러스 벡터가 보다 급성장을 이룰 전망
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

LSH 25.07.15

Global Gene Therapy Market to Reach US$6.0 Billion by 2030

The global market for Gene Therapy estimated at US$1.7 Billion in the year 2024, is expected to reach US$6.0 Billion by 2030, growing at a CAGR of 23.0% over the analysis period 2024-2030. Viral, one of the segments analyzed in the report, is expected to record a 23.3% CAGR and reach US$5.5 Billion by the end of the analysis period. Growth in the Non-Viral segment is estimated at 20.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$928.9 Million While China is Forecast to Grow at 29.5% CAGR

The Gene Therapy market in the U.S. is estimated at US$928.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$216.3 Million by the year 2030 trailing a CAGR of 29.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 20.1% and 22.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 22.0% CAGR.

Global Gene Therapy Market - Key Trends & Drivers Summarized

Revolutionizing Medicine: How Gene Therapy Is Redefining Treatment Paradigms?

Gene therapy represents a groundbreaking medical approach that involves modifying the genetic material within a person's cells to treat or prevent disease. This innovative therapy can potentially provide a cure for a range of disorders by correcting defective genes responsible for disease development. Techniques used in gene therapy include replacing a mutated gene that causes disease with a healthy copy, inactivating a mutated gene that is functioning improperly, or introducing a new or modified gene into the body to help treat a disease. These methods are primarily delivered through vectors, typically viruses that have been genetically altered to carry human DNA. The potential of gene therapy extends from treating hereditary diseases like cystic fibrosis and hemophilia to more complex conditions such as cancer, heart disease, and HIV/AIDS. Its development represents a significant leap from traditional treatments, offering hope for long-term or permanent therapeutic effects after a single treatment course.

Pushing the Boundaries: Next-Generation Techniques Enhancing Gene Therapy

Technological advancements have significantly improved the precision and efficacy of gene therapy. The advent of CRISPR-Cas9 and other gene-editing technologies has provided scientists with tools of unprecedented accuracy for editing DNA at specific locations, allowing for the correction of mutations at their source. These advancements not only increase the potential for successful treatment outcomes but also reduce the risks associated with older gene therapy methods, such as unintended effects on other parts of the genome. Additionally, innovations in vector technology, particularly in the development of non-viral delivery systems, are overcoming previous challenges related to safety and immune response management. These enhancements in delivery systems ensure that therapeutic genes reach the target cells more effectively and work as intended, which is critical for the treatment of diseases that require cellular-level interventions.

Navigating Complexities: The Challenges and Ethical Dilemmas of Modern Gene Therapy

Despite its promising potential, gene therapy faces several challenges and ethical considerations that influence its clinical application. One of the primary challenges is ensuring long-term safety and efficacy, as the long-term effects of gene editing are still not fully understood. Questions remain about the potential for off-target effects, where unintended parts of the genome may be edited, leading to unforeseen consequences. Additionally, the immune system's response to viral vectors can complicate delivery and effectiveness, particularly for patients who might have pre-existing immunity to the viruses used as vectors. Ethical concerns also play a significant role, particularly regarding germline editing, which could allow genetic changes to be passed down to future generations. The debate centers on the implications of making genetic modifications that could alter human evolution, underscoring the need for rigorous ethical standards and regulatory oversight in the development and application of gene therapy treatments.

Fueling a Medical Revolution: Key Drivers Behind the Expanding Gene Therapy Market

The growth in the gene therapy market is driven by several factors, including significant advancements in genetic research and biotechnological techniques. The increasing prevalence of genetic disorders and high unmet need for novel treatments in oncology, neurology, and rare diseases are major market drivers. The successful commercialization of several gene therapies in recent years has demonstrated the potential for substantial returns on investment, attracting more funding for research and development in this field. Additionally, regulatory incentives, such as orphan drug designations and accelerated approvals, encourage the development of gene therapies for rare and severe conditions. Consumer behavior, particularly the growing demand for personalized medicine and treatments that offer durable to permanent cures, also propels the market forward. Moreover, collaborations between biotech firms, pharmaceutical companies, and academic institutions are fostering innovation and speeding the translation of gene therapy from research to clinical settings. These factors, combined with the increasing global capacity for biopharmaceutical manufacturing, ensure continued growth and expansion of gene therapy solutions, making it one of the most dynamic and transformative fields in modern medicine.

SCOPE OF STUDY:

The report analyzes the Gene Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vector Type (Viral, Non-Viral); Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Other Applications)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 154 Featured) -

  • Amgen, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Bionomics Ltd.
  • BioMarin Pharmaceutical, Inc.
  • AnGes, Inc.
  • Amicus Therapeutics, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • bluebird bio, Inc.
  • Advantagene, Inc.
  • Biogen, Inc.
  • Abeona Therapeutics
  • Aptah
  • Avrobio
  • Arbor Biotechnologies, Inc.
  • Biocardia, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Gene Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • By Vector Type
  • VIRAL VECTORS ACCOUNT FOR A MAJOR SHARE OF THE MARKET
    • Adeno-Associated Virus Vectors
    • Lentivirus
  • NON-VIRAL VECTORS TO WITNESS FASTER GROWTH
    • US and Europe Dominate the Gene Therapy Market
    • Oncology Represents the Largest Indication for Gene Therapy
    • Market Outlook
    • Recent Market Activity
    • Select Innovations
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Availability of Novel Therapies Drive Market Growth
    • Select Approved Gene Therapy Products
    • Adeno-associated Virus Vectors - A Leading Platform for Gene Therapy
    • Lentiviral Vectors Witness Increasing Interest
    • Rising Cancer Incidence Worldwide Spurs Demand for Gene Therapy
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Compelling Level of Technology & Innovation to Ignite Gene Therapy
    • Promising Gene Therapy Innovations for Treatment of Inherited Retinal Diseases
    • Gene Therapy Pivots M&A Activity in Dynamic Domain of Genomic Medicine
    • M&As Rampant in Gene Therapy Space
    • Emphasis on Formulating Robust Regulatory Framework
    • Strong Gene Therapy Pipeline
    • Gene Therapy: Phase III Clinical Trials
    • OHSU Implements First-Ever LCA10 Gene Therapy Clinical Trial with CRISPR
    • Growing Funding for Gene Therapy Research
    • Market Issues & Challenges
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 3: World 13-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2017, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 6: World 13-Year Perspective for Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Non-Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Non-Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 9: World 13-Year Perspective for Non-Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 12: World 13-Year Perspective for Oncological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 15: World 13-Year Perspective for Rare Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 18: World 13-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 21: World 13-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2025 & 2030
    • TABLE 22: World Gene Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2017 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 25: USA 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 28: USA 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 31: Canada 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 34: Canada 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • JAPAN
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 37: Japan 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 40: Japan 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • CHINA
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 43: China 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 46: China 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • EUROPE
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 49: Europe 13-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2017, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 52: Europe 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 55: Europe 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • FRANCE
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 58: France 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 61: France 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • GERMANY
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 64: Germany 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 67: Germany 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 70: Italy 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 73: Italy 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • UNITED KINGDOM
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 76: UK 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 79: UK 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 82: Rest of Europe 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 85: Rest of Europe 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • ASIA-PACIFIC
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 88: Asia-Pacific 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 91: Asia-Pacific 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 94: Rest of World 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 97: Rest of World 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제